appliedclinicaltrialsonline4 小时
ASTRO Trial Shows SC Tremfya Provides Significant Clinical Benefits in Moderately to ...
Tremfya could become the first IL-23 inhibitor with fully subcutaneous induction and maintenance options in the treatment of ...